title: Oncoprotein c-erbB-2 in squamous cell carcinoma of the uterine cervix and evaluation of its significance in response of disease to treatment.
abstract: Tissues from 50 cases of squamous cell carcinoma of the uterine cervix were analysed for immunohistochemical expression of c-erbB-2 oncoprotein and the patients were followed-up for 2 years. Immunopositivity of c-erbB-2 was studied with reference to clinical stage, histopathological differentiation and response to the cancer therapy. Expression of c-erbB-2 protein was found to be higher (37.5%) in cases with stage II disease, whereas more expressions were noticed in poorly differentiated squamous cell carcinoma (33.3%). Among cases who showed complete response to the treatment, 20.8% were positive for c-erbB-2 oncoprotein. On the contrary, 36.8% of prognostically unfavourable cases revealed positivity for c-erbB-2 immunostaining. However, the difference between c-erbB-2 expressions of these two said groups of patients, which were divided in accordance with the response to treatment, did not attain to statistical significance. Study on c-erbB-2 among larger number of patients with cervical carcinoma may prove to be an important factor in response to cancer therapy.
authors.affiliation: Department of Radiotherapy, All India Institute of Medical Sciences, New Delhi-110 029.
authors.forename: M
authors.initials: M
authors.lastname: Bhadauria
authors.forename: A
authors.initials: A
authors.lastname: Ray
authors.forename: R K
authors.initials: RK
authors.lastname: Grover
authors.forename: S
authors.initials: S
authors.lastname: Sharma
authors.forename: S L
authors.initials: SL
authors.lastname: Naik
authors.forename: B K
authors.initials: BK
authors.lastname: Sharma
mesh_terms: D000328:Adult; D002294:Carcinoma, Squamous Cell / Q000737:chemistry* / Q000628:therapy; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D002583:Uterine Cervical Neoplasms / Q000737:chemistry* / Q000628:therapy
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases